Mankind Pharma’s IPO will hit the market next week. Here are 10 important things about the offer

Mankind Pharma The listing of its equity shares expects to enhance its visibility and brand, while providing liquidity to its existing shareholders.

Here are 10 key takeaways from the Mankind IPO:

1. the IPO Will open on 25th April and will be available for subscription for a period of 3 days. Bidding will close on 27 April. Anchor investors bidding before the IPO will happen on 24 April.

2. The IPO is a pure OFS where shareholders will offload a total of 40,058,844 equity shares. Mankind will not receive any proceeds from the IPO as the funds will go to the selling shareholders.

3. Among the selling shareholders, Chairman Ramesh Juneja will sell 3,705,443 equity shares. While Mankind Vice Chairman and Managing Director Rajeev Juneja will sell 3,505,149 equity shares. Sheetal Arora, another promoter, will sell 2,804,119 equity shares. The remaining shares in the OFS will be sold by investors such as Cairnhill CIPEF, Cairnhill CGPE, Bez Limited and Link Investment Trust.

4. The price for the IPO is fixed at the lower end of the band 1,026 per share and upper end 1,080 per share.

5. 50% of the shares offered for sale are reserved for Qualified Institutional Buyers (QIBs). Meanwhile, 15% will be kept for non-institutional investors (NIIs) and the remaining 35% will be allotted to retail individual investors (RIIs).

6. Firms such as Kotak Mahindra Capital Company, Axis Capital, IIFL Securities, Jefferies India and JP Morgan India are acting as Book-Running Lead Managers (BRLMs) of the IPO. Kefin Technologies is the registrar to the issue.

7. Post listing, Mankind will compete against pharmaceutical giants such as Sun Pharma, Cipla, Zydus Lifesciences, Torrent Pharma, Alkem Laboratories, Eris Lifesciences, GlaxoSmithKline Pharmaceuticals, and Dabur India.

8. Mankind looks to continue to grow its covered market presence and strengthen its position in IPM. In addition, the company is also focused on pursuing opportunities in therapeutic areas to expand its presence. In addition, the company is committed to increasing its penetration in metros and tier-I cities such as Delhi NCR, Bengaluru, Mumbai, Hyderabad, Cochin, Chennai and Kolkata. The company already has a substantial share of domestic sales in tier II-IV cities and rural markets as compared to IPM.

9. As part of its strategies to grow its healthcare business, Mankind plans to launch a new preconception and prenatal care range of products as a brand extension under its Prega News brand. Last year, in November, the company completed the cash acquisition for a majority stake in Upakarma Ayurveda, which is expected to provide Mankind a direct-to-customer channel in the Ayurvedic medicine category.

10. The net profit of the company as on December 31, 2022 was 1,015.98 crore, and the revenue from operations was 6,696.78 crores. Mankind has shown consistent growth in financial results between FY22 to FY20. total income climbed 7,977.58 crore in FY22 Vs. 6,385.38 crore and 5,975.65 crore in FY21 and FY20. PAT has jumped 1,452.96 crore in FY22 as compared to Rs. 1,293.03 crore in FY21 and 1,056.15 crore in FY20.

Mankind is the fourth largest pharmaceutical company in India in terms of domestic sales and the third largest in terms of sales volume for MAT as of December 31, 2022. The company is engaged in the development, manufacturing and marketing of a wide variety of pharmaceutical formulations for the acute and chronic therapeutic areas as well as a number of consumer health care products.